Your browser doesn't support javascript.
Serum syndecan-1 reflects organ dysfunction in critically ill patients.
Suzuki, Keiko; Okada, Hideshi; Sumi, Kazuyuki; Tomita, Hiroyuki; Kobayashi, Ryo; Ishihara, Takuma; Kakino, Yoshinori; Suzuki, Kodai; Yoshiyama, Naomasa; Yasuda, Ryu; Kitagawa, Yuichiro; Fukuta, Tetsuya; Miyake, Takahito; Okamoto, Haruka; Doi, Tomoaki; Yoshida, Takahiro; Yoshida, Shozo; Ogura, Shinji; Suzuki, Akio.
  • Suzuki K; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Okada H; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. hideshi@gifu-u.ac.jp.
  • Sumi K; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Tomita H; Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan.
  • Kobayashi R; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Ishihara T; Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan.
  • Kakino Y; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Suzuki K; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Yoshiyama N; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Yasuda R; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Kitagawa Y; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Fukuta T; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Miyake T; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Okamoto H; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Doi T; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Yoshida T; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Yoshida S; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Ogura S; Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Suzuki A; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. akio@gifu-u.ac.jp.
Sci Rep ; 11(1): 8864, 2021 04 23.
Article in English | MEDLINE | ID: covidwho-1242039
ABSTRACT
Syndecan-1 (SDC-1) is found in the endothelial glycocalyx and shed into the blood during systemic inflammatory conditions. We investigated organ dysfunction associated with changing serum SDC-1 levels for early detection of organ dysfunction in critically ill patients. To evaluate the effect of SDC-1 on laboratory parameters measured the day after SDC-1 measurement with consideration for repeated measures, linear mixed effects models were constructed with each parameter as an outcome variable. A total of 94 patients were enrolled, and 831 samples were obtained. Analysis using mixed effects models for repeated measures with adjustment for age and sex showed that serum SDC-1 levels measured the day before significantly affected several outcomes, including aspartate aminotransferase (AST), alanine transaminase (ALT), creatinine (CRE), blood urea nitrogen (BUN), antithrombin III, fibrin degradation products, and D-dimer. Moreover, serum SDC-1 levels of the prior day significantly modified the effect between time and several outcomes, including AST, ALT, CRE, and BUN. Additionally, increasing serum SDC-1 level was a significant risk factor for mortality. Serum SDC-1 may be a useful biomarker for daily monitoring to detect early signs of kidney, liver and coagulation system dysfunction, and may be an important risk factor for mortality in critically ill patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Critical Illness / Syndecan-1 / Multiple Organ Failure Type of study: Experimental Studies / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-88303-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Critical Illness / Syndecan-1 / Multiple Organ Failure Type of study: Experimental Studies / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-88303-7